A Study Investigating Lu AG06466 in Healthy Men

Inclusion Criteria: * The participant has a body mass index (BMI) ≥18.5 and ≤30 kilograms (kg)/square meter (m\^2) and a body weight of ≥60 kg at the Screening Visit and at the Baseline Visit. * The participant has a resting supine systolic blood pressure ≥91 and ≤140 millimeters of mercury (mmHg) and a resting supine diastolic blood pressure ≥51 and ≤85 mmHg at the Screening Visit and at the Baseline Visit. * The participant is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, neurological examination, vital signs, an electrocardiogram (ECG), and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests. Exclusion Criteria: * The participant has taken disallowed medication \<1 week prior to the first dose of study drug or \<5 half-lives prior to the Screening Visit for any medication taken. * The participant has orthostatic hypotension, defined as a decrease in systolic blood pressure ≥20 mmHg or a decrease in diastolic blood pressure ≥10 mmHg from supine to standing, at the Screening Visit or at the Baseline Visit. * The participant has or has had any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, or psychiatric disease or other major disorder. * The participant has received a COVID-19 vaccination less than 30 days prior to the first dose of study drug. * The participant trains/exercises intensively, for example, for a marathon or triathlon, or at a competitive level. * The participant is exposed to significant levels of ionizing radiation at work. * The participant has undergone any clinical procedures involving significant exposure to radiation (excluding dental X-ray and common X-rays of the chest or extremities) \<12 months prior to the Screening Visit. * The participant has received radiolabelled material \<12 months prior to the Screening Visit. Note: Other inclusion and exclusion criteria may apply.